908 Devices enhances MX908 usability and adds new drug targets. 908 Devices Inc. has announced new capabilities for its handheld MX908 mass spectrometry device for trace chemical identification. These enhancements include an updated mission mode for hazardous vapor sampling and the addition of five priority drug targets, providing first responders with intelligence at the point of need for an informed, confident response. The MX908 mission modes, which include Drug Hunter, Explosives Hunter, and CW (chemical warfare) Hunter, have matured into the most powerful and complete capabilities in the device, offering broader coverage and higher confidence in results. The device's Hazard Survey mode originally provided users with a broad, but less detailed analysis, and is now replaced with TIC (toxic industrial chemical) Hunter as a dedicated mission mode for focused hazardous vapor detection. This new mode provides first responders with a more guided and purpose-built tool that delivers clearer, faster conclusions for real-world response scenarios. To keep pace with an evolving illicit drug landscape, five drug targets have been added to the MX908, including medetomidine, a non-opioid, veterinary sedative that is often mixed with fentanyl. Also known as 'rhino tranq', medetomidine is estimated to be 200 times more potent than xylazine, another veterinary sedative, making even small amounts of the drug extremely dangerous to humans. First reported in the Philadelphia drug supply in mid-2024, and spreading to other Eastern and Midwestern cities, this potent sedative causes severe withdrawal symptoms that often require intensive medical care. Other drug targets added to MX908 include a synthetic cathinone, two synthetic cannabinoids and a benzodiazepine. * Synthetic cathinone: N-isopropyl butylone, which has quickly emerged as the second most reported stimulant in the latter half of 2025, and is a Schedule I substance in the U.S. * Synthetic cannabinoids: ADB-PINACA, a Schedule I substance, and MDMB-BINACA, which has been observed in the U.S., Canada, U.K., Europe, and Asia * Benzodiazepine: Bromazolam, which is frequently found mixed with other drugs, including fentanyl "These latest enhancements reinforce MX908's unmatched capability for rapid trace chemical identification at the point of need," said Trey Sieger, senior director of product management at 908 Devices. "By delivering fast, reliable results, MX908 equips law enforcement officers, military personnel, and hazmat teams with actionable intelligence they can trust to make critical decisions when every second counts." Customers can add these new capabilities to their MX908 device through a software update, available via the 908 Devices Customer Support Portal. The MX908 utilizes high-pressure mass spectrometry (HPMS) for chemical identification at trace levels with exceptional sensitivity and unmatched selectively, empowering first responders to make swift, informed decisions at the point of need. The MX908 is set apart by its ability to detect trace levels of drugs, explosives and other hazardous materials in all forms - solids, liquids, vapors and aerosols.

908 Devices has declared an "inflection point" for the company, targeting 15–20% revenue growth in 2026 as demand rises for field-based chemical detection devices used by law enforcement, federal agencies and military customers globally. The company has deployed over 3,700 devices across 700 accounts with more than 18,000 trained users. Its products detect illicit drugs like fentanyl, toxic chemicals and advanced agents at the point of need. For 2025, 908 Devices reported 18% year-over-year growth from continuing operations, positive adjusted EBITDA in Q4, and 57% adjusted gross margin. The company ended the year with $113 million in cash. Management said it transformed the business by divesting desktop products and focusing on handheld mass spectrometry and FTIR optical technologies. In 2025, approximately 50% of placements were beyond its core mass spectrometry product.